Primary Care/Hospitalist
RSSArticles
-
Managing Stress to Improve GERD Symptoms
The researchers’ goal was to address the fact that therapies that are adjunctive to proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD) have been under studied. In this clinical trial, an education intervention was examined in adult patients with GERD recruited from rural general practices in England. -
Testosterone Therapy – Recommendations Resulting from Two Recent Clinical Trials
The prescription rate of testosterone therapy has increased dramatically in the last decade, and primary care practitioners are asked on a daily basis about testosterone supplementation. Ingenious marketing has led many patients — many of whom are older and have risk factors for heart disease — to question if testosterone therapy is right for them. -
Clinical Briefs
Johnston BC, et al. Comparison of weight loss among named diet programs in overweight and obese adults: A meta-analysis. -
Updates and Future Direction on Medical Uses for Probiotics
The probiotic movement is rapidly growing and, although to date no probiotics have been approved by the FDA, they are actively marketed to the public as either foods or dietary supplements. It behooves the primary care physician to be familiar with the science, indications, and appropriate usage of probiotic therapies. -
Aspirin for the Prevention of Recurrent Venous Thromboembolism
Patients with unprovoked venous thromboembolism (VTE) are at high risk of recurrence after discontinuation of vitamin K antagonist (such as warfarin) therapy, with an approximately 10% risk of recurrence within the first year and 5% risk per year thereafter. -
Probiotic Supplementation Reduces Upper Respiratory Tract Infections
This 150-day, randomized, double-blind, placebo controlled trial (RCT) with 465 healthy adult volunteers (mean age 37 years old) was designed to examine the effects of probiotics on the incidence of upper respiratory tract infections (URTI). -
Pirfenidone Capsule (Esbriet®) and Nintedanib Capsules (Ofev®)
The FDA has approved two drugs for the treatment of idiopathic pulmonary fibrosis (IPF). Pirfenidone is an antifibrotic agent and nintedanib is a tyrosine kinase inhibitor. Both products were approved on a fast-track priority review, with orphan status and breakthrough designation. Pirfenidone is marketed by InterMune as Esbriet and nintedanib as Ofev by Boehringer Ingelheim. -
The Holy Grail of Diagnosing Depression: An Effective Blood Test
An objective, laboratory based diagnostic tool for depression would be extremely helpful to primary care physicians. This study using nine biomarkers holds promise that a blood test may be able to identify depressed patients among non-depressed primary care patients -
The Photosensitive Patient
A 65-year-old female presents to the emergency department with a chief complaint of a severe rash. The rash has been present for two weeks on her arms, neck, and scalp. It began while she was sitting on her porch one afternoon. She denies any associated fevers, chills, headache, or muscle ache. She denies any exposure to pets, new soaps, detergents, or lotions, and she denies recent travel.
-
Emergency Medicine Reports - Full November 30, 2014 Issue in PDF